The gastric cancer diagnostic market was valued at $2.3 billion in 2022 and is estimated to reach $3.8 million by 2032, exhibiting a CAGR of 5.3% from 2023 to 2032. Gastric cancer diagnostic refers to the process of identifying and confirming the presence of gastric (stomach) cancer in an individual. It involves various medical procedures and tests aimed at detecting and diagnosing this type of cancer. The goal of gastric cancer diagnostics is to determine if a person has malignant (cancerous) growth in the stomach, understand its characteristics, including the type and stage of the cancer, and provide valuable information to guide treatment decisions. Gastric cancer has become the second leading cause of cancer-related deaths worldwide, and its epidemiology has undergone significant changes in recent decades. During endoscopy or surgery, a tissue sample (biopsy) is collected from the suspicious area in the stomach. The biopsy is then examined by a pathologist to confirm the presence of cancer and determine its type and grade.
The gastric cancer diagnostic market has experienced significant growth owing to rise in prevalence of gastric cancer and advancements in diagnostics technology. For instance, according to the National Library of Medicine, a total of 1,089,103 new stomach cancer cases were reported globally for 2020. In addition, rise in awareness, screening programs about the importance of stomach cancer screening and the implementation of organized screening programs in some regions lead to early detection and diagnosis of gastric cancer, which fuels the market growth.?
Furthermore, the rise in trend toward personalized or precision medicine fosters the use of molecular and genetic testing to identify specific genetic markers and tailor treatments to individual patients, boosting the demand for diagnostic tests and propelling the market growth. Furthermore, the ongoing advancements in diagnostic tools and technologies, such as improved endoscopy, molecular & genetic testing, and imaging techniques, enhance the accuracy and early detection of gastric cancer, which is expected to drive the market growth.?
The gastric cancer diagnostic market is segmented into product, disease type, end user, and region. By product, the market is segregated into reagents & consumables and instruments. By disease type, the market is categorized into adenocarcinoma, gastric lymphoma, and others. By end user, the market is classified into hospitals, diagnostic laboratories, and diagnostic imaging centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).?
Major key players that operate in the gastric cancer diagnostic market are Bio-Rad Laboratories, Inc., Qiagen NV., Agilent Technologies, Inc., Exact Sciences Corporation, MiRXES Pte Ltd, Hipro Biotechnology Co.,Ltd., Fulgent Genetics, Endofotonics Pte Ltd, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the gastric cancer diagnostic market.??

KEY BENEFITS FOR STAKEHOLDERS
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer diagnostic market analysis from 2022 to 2032 to identify the prevailing gastric cancer diagnostic market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the gastric cancer diagnostic market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global gastric cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client’s interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)

KEY MARKET SEGMENTS
By Product
- Reagents and Consumables
- Instruments
By Disease Type
- Adenocarcinoma
- Gastric Lymphoma
- Others

By End Users
- Hospitals
- Diagnostic Laboratories
- Diagnostic Imaging Centers

By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Exact Sciences Corporation
- Fulgent Genetics
- Endofotonics Pte Ltd
- MiRXES Pte Ltd
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Hipro Biotechnology Co.,Ltd.
- Abbott Laboratories
- Qiagen NV.
- Bio-Rad Laboratories, Inc.